Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: A systematic review and meta-analysis
Cardiovascular Diabetology Feb 09, 2022
In patients hospitalized for acute heart failure (AHF), sodium-glucose cotransporter 2 (SGLT2) inhibitors initiation during hospitalization or early post-discharge (within 3 days) was found to be associated with decreased risk of rehospitalization for heart failure and improved patient-reported outcomes with no excess risk of adverse impacts.
In this systematic review and meta-analysis of three randomized controlled trials with a total of 1,831 patients, the efficacy as well as safety of SGLT2 inhibitors initiated in patients hospitalized for AHF was assessed.
In AHF cases, SGLT2 inhibitors initiation led to decreased risk of rehospitalization for heart failure (odds ratio,OR: 0.52) and improved Kansas City Cardiomyopathy Questionnaire scores (mean difference 4.12).
Initiation of SGLT2 inhibitors did not statistically significantly impact all-cause mortality (OR 0.70).
Initiation of SGLT2 inhibitors did not increase the acute kidney injury (OR 0.76), hypotension (OR 1.17), or hypoglycemia (OR 1.51).
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries